Drug intelligence / Profile preview

Qushi Tongluo formula

Development stage: Unknown
Lead developer: Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Administration: Oral

Overview

Qushi Tongluo formula is a Traditional Chinese Medicine (TCM) herbal preparation developed by the Affiliated Hospital of Shandong University of Traditional Chinese Medicine. It is primarily investigated as an adjuvant therapy for the treatment of drug-resistant *Mycoplasma pneumoniae* pneumonia (DRMPP) in children. The formula is administered as oral granules in combination with standard intravenous macrolide antibiotics. Its therapeutic mechanism is rooted in TCM principles of 'dispelling dampness' (Qushi) and 'unblocking collaterals' (Tongluo), with clinical studies focusing on its ability to modulate immune function and reduce systemic inflammatory markers in patients with refractory respiratory infections.

Other names: Qushi Tongluo formula granules

Beyond the preview

Go deeper on Qushi Tongluo formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qushi Tongluo formula.

Explore the full profile